RxDoctor Payments Data

Richard Wang, MD

Internal Medicine · Flushing, NYNPI 1235208455

Payments from drug & device makers

$4,488in general payments, 2019–2025

Across 186 payments — averaging $24.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$3K
  • AstraZeneca$495
  • Novo Nordisk$357
  • Lilly USA, LLC$230
  • Amarin Pharma, Inc.$183
  • Merck$177
  • plus $369 from 9 others

What the payments were for

  • Food & beverage$4,477100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,488 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$7,750
Medicare patients
16
Services billed
83

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VascepaIcosapent Ethyl833$330,462
JardianceEmpagliflozin282$203,947
Diclofenac Epolamine241$177,289
Diclofenac Sodium363$108,627
EliquisApixaban122$94,036
RybelsusSemaglutide77$90,176
VemlidyTenofovir Alafenamide57$81,270
JanuviaSitagliptin Phosphate94$62,208
Lactulose39$46,172
Clemastine Fumarate22$45,413
FarxigaDapagliflozin Propanediol52$32,587
JanumetSitagliptin Phos/Metformin Hcl31$27,526
Icosapent Ethyl125$23,002
TradjentaLinagliptin34$22,281
RestasisCyclosporine32$19,944

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$38$226,229316 claims
Novo NordiskRybelsus, Ozempic$357$107,91797 claims
MerckJanuvia, Janumet$177$89,733125 claims
GileadVemlidy$2,677$81,27057 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$495$55,132106 claims
AbbVieRestasis$145$19,94432 claims
Johnson & JohnsonXarelto$29$15,25316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Flushing

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →